RxDoctor Payments Data

Nicholas Deyoung, PA

Physician Assistant · Mesa, AZNPI 1336615590

Payments from drug & device makers

$4,335in general payments, 2019–2025

Across 160 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$1K
  • Endo USA, Inc.$629
  • Antares Pharma, Inc.$480
  • Boston Scientific$319
  • Coloplast$316
  • Astellas Pharma US Inc$238
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$66015%
  • Speaking & faculty fees$511%
  • Food & beverage$3,56982%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,335 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$178,543
Medicare patients
612
Services billed
2,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$42,596
GemtesaVibegron29$16,918
Testosterone48$7,557
Tamsulosin Hcl267$4,568
Testosterone Cypionate65$3,015
Alfuzosin Hcl ErAlfuzosin Hcl75$2,046
Dutasteride31$1,601
Finasteride93$1,415
Solifenacin Succinate30$1,123
Tadalafil11$885
Estradiol16$858
NyamycNystatin24$167
Cephalexin12$84
Anastrozole17$41
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$238$42,59659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →